 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 The Mayo researchers found that pom/dex was helpful in 29 percent of patients who didn't respond to lenalidomide.
The interim results of the study, funded by Celgene, were presented at the annual meeting of the American Society of Hematology.
"We are excited about the potential of this drug combination to significantly help patients with myeloma. Based on these encouraging results, we are expanding the study to include other patient populations that may benefit from this therapy," Lacy said.
Text Continues Below
More information
The American Cancer Society has more about multiple myeloma.
Page: << Prev | 1 | 2
-- Robert Preidt
|
.gif)
